In primary care/internal medicine, combination therapy typically consists of DTE as the preferred approach in patients failing to respond to LT4 monotherapy. Can you provide a roadmap for DTE use—including NP Thyroid and other formulations?

In primary care/internal medicine, combination therapy typically consists of DTE as the preferred approach in patients failing to respond to LT4 monotherapy. Can you provide a roadmap for DTE use—including NP Thyroid and other formulations?

In primary care/internal medicine, combination therapy typically consists of DTE as the preferred approach in patients failing to respond to LT4 monotherapy. Can you provide a roadmap for DTE use—including NP Thyroid and other formulations?


Created by

CMEducation Resources IQ&A Thyroid Hormone Replacement Medical Intelligence Zone

Presenter

Francesco Saverio Celi, MD, MHSc

Francesco Saverio Celi, MD, MHSc

William G. Blackard Professor of Medicine Chair, Division of Endocrinology Diabetes and Metabolism Department of Internal Medicine Virginia Commonwealth University Director, VCU Health Diabetes Program Richmond, Virginia